75 related articles for article (PubMed ID: 26935338)
1. Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine.
Sui D; Ma L; Li M; Shao W; Du H; Li K; Li Z; Li Z
Mol Med Rep; 2016 Apr; 13(4):3675-83. PubMed ID: 26935338
[TBL] [Abstract][Full Text] [Related]
2. B16 cell lysates plus polyinosinic-cytidylic acid effectively eradicate melanoma in a mouse model by acting as a prophylactic vaccine.
Lin B; Zhao H; Fan J; Xie F; Wang W; Ding X
Mol Med Rep; 2014 Aug; 10(2):911-6. PubMed ID: 24840631
[TBL] [Abstract][Full Text] [Related]
3. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.
Hokey DA; Larregina AT; Erdos G; Watkins SC; Falo LD
Cancer Res; 2005 Nov; 65(21):10059-67. PubMed ID: 16267032
[TBL] [Abstract][Full Text] [Related]
4. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
7. CD11c+ blood dendritic cells induce antigen-specific cytotoxic T lymphocytes with similar efficiency compared to monocyte-derived dendritic cells despite higher levels of MHC class I expression.
Radford KJ; Turtle CJ; Kassianos AJ; Hart DN
J Immunother; 2006; 29(6):596-605. PubMed ID: 17063122
[TBL] [Abstract][Full Text] [Related]
8. Ginsenoside Rg1 Activates Dendritic Cells and Acts as a Vaccine Adjuvant Inducing Protective Cellular Responses Against Lymphomas.
Huang Y; Zou Y; Lin L; Zheng R
DNA Cell Biol; 2017 Dec; 36(12):1168-1177. PubMed ID: 29058460
[TBL] [Abstract][Full Text] [Related]
9. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.
Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M
Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226
[TBL] [Abstract][Full Text] [Related]
10. MUC1 and maltose‑binding protein recombinant fusion protein combined with Bacillus Calmette‑Guerin induces MUC1‑specific and nonspecific anti‑tumor immunity in mice.
Fang F; Ma J; Ni W; Wang F; Sun X; Li Y; Li Q; Xie F; Wang J; Zhai R; Liu Z; Gao S; Tai G
Mol Med Rep; 2014 Aug; 10(2):1056-64. PubMed ID: 24912810
[TBL] [Abstract][Full Text] [Related]
11. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
12. A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth.
Yuan S; Shi C; Lv Y; Wang T; Wang H; Han W
Cancer Biother Radiopharm; 2009 Oct; 24(5):607-13. PubMed ID: 19877891
[TBL] [Abstract][Full Text] [Related]
13. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
14. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
[TBL] [Abstract][Full Text] [Related]
15. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
16. Novel vaccination protocol consisting of injecting MUC1 DNA and nonprimed dendritic cells at the same region greatly enhanced MUC1-specific antitumor immunity in a murine model.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Tezuka N; Sawai S; Inoue S; Fujino S; Maeda T; Itoh Y; Ogasawara K; Sato H; Ohkubo I; Kudo T
Cancer Gene Ther; 2002 Apr; 9(4):330-7. PubMed ID: 11960283
[TBL] [Abstract][Full Text] [Related]
17. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.
Turner MS; Cohen PA; Finn OJ
J Immunol; 2007 Mar; 178(5):2787-93. PubMed ID: 17312122
[TBL] [Abstract][Full Text] [Related]
18. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
19. A Synthetic MUC1 Anticancer Vaccine Containing Mannose Ligands for Targeting Macrophages and Dendritic Cells.
Glaffig M; Stergiou N; Hartmann S; Schmitt E; Kunz H
ChemMedChem; 2018 Jan; 13(1):25-29. PubMed ID: 29193802
[TBL] [Abstract][Full Text] [Related]
20. Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
Li B; VanRoey MJ; Jooss K
Clin Immunol; 2007 May; 123(2):155-65. PubMed ID: 17320482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
